The treatments combine monoclonal antibodies (mAbs) alongside potent anti-cancer agents, often a small molecule drug, combined through a chemical linker ... year shares in Mersana Therapeutics ...

The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee’s continued service with Mersana on each such vesting date. The RSU ...

William Blair initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating.Maximize Your Portfolio with Data Driven ...

Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...

On Thursday, William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug ...

CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...